Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and pricing challenges loom. See more here.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help anchor top-line growth,” the Citi analysts wrote in their note.

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32%

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and diabetes treatment Mounjaro continued to soar.